Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
CB Therapeutics logo — CB Therapeutics produces high value molecules, compounds and...

CB Therapeutics

CB Therapeutics produces high value molecules, compounds and rare ingredients with novel, proprietary SynBio platforms.

Founded 2015 United States Carlsbad, United States 15 employees Series A Total: $7.62M Biotechnology, Health and Wellness

General Information

Company Name CB Therapeutics
Founded Year 2015
Location United States Carlsbad, United States
Founders / Decision Makers
Team member Team member Team member
Employees 15
Industries Biotechnology, Health and Wellness
Funding Stage Series A
Business Model B2B, White Label
Revenue Model Product Sales, Licensing, Project Based
Social

BounceWatch is an independent company data service, not affiliated with CB Therapeutics. To contact CB Therapeutics, visit cbthera.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does CB Therapeutics compare?

A PDF of CB Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting CB Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About CB Therapeutics

CB Therapeutics, founded in 2015 and headquartered in the United States, is at the forefront of biotechnology innovation. Specializing in high-value molecules and rare ingredients, their proprietary SynBio platforms leverage synthetic genomics and bio-engineering to produce complex compounds using yeast, bacteria, and cell-free systems.

The company emphasizes sustainable and efficient production, delivering compounds like tryptamines and cannabinoids with unmatched purity and yield. By focusing on neuroscience, CB Therapeutics aims to address critical mental health and societal challenges through advanced therapeutics.

Their progress in the Health and Wellness sector was marked by a Series A investment on 04 January 2023, demonstrating investor confidence in their technological capabilities and market potential. With a commitment to sustainability and innovation, CB Therapeutics is positioned to lead in the biotech landscape.

Business keywords: Synthetic Biology, Bio-engineering, Synthetic Genomics, Tryptamines, Cannabinoids, Neuroscience, Mental Healthcare, Phytochemicals, Cellular Production

Services & Products

Development of rare compounds using synthetic biology
Production of cannabinoids, tryptamines, and peptides
AI-driven biosynthesis platform for enzyme and pathway design
Creation of animal-free food ingredients
Research and development for non-opioid pain management

Target Customers

Pharmaceutical Companies Biotechnology Firms Food and Beverage Industry Mental Health Research Institutions Wellness and Supplement Manufacturers

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Series A Undisclosed -
04 Jan 2023
Venture Round Undisclosed 1
Mystic Ventures
Mystic Ventures
01 Oct 2022
Series A Undisclosed 1
re.Mind Capital
re.Mind Capital
10 May 2021
Venture Round $7.50M -
16 Apr 2019
Seed Round $120.00K 3
Y Combinator Fort Ventures
Y Combinator, Fort Ventures +1
20 Aug 2018
Seed Round Undisclosed 1
Pioneer Fund
Pioneer Fund
15 Aug 2018
Non Equity Assistance Undisclosed 1
EvoNexus
EvoNexus
06 Jun 2017

CB Therapeutics Alternatives & Competitors

View All Alternatives
CB Therapeutics vs
Berkeley Lights
Berkeley Lights United States

Accelerate your path to live cell function and recovery

Debt Financing
51 employees
Biopharma, Biotechnology
CB Therapeutics vs
CERo Therapeutics, Inc.
CERo Therapeutics, Inc. United States

Tumor Cell Clearance Reimagined.

Series A
16 employees
Biotechnology, Health and Wellness
CB Therapeutics vs
Koniku
Koniku United States

Bio is Tech™

Series A
6 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About CB Therapeutics

CB Therapeutics produces high value molecules, compounds and rare ingredients with novel, proprietary SynBio platforms.
CB Therapeutics was founded in 2015.
CB Therapeutics is headquartered in Carlsbad, United States.
CB Therapeutics operates in Biotechnology and Health and Wellness. Its work centres on Synthetic Biology, Bio-engineering, Synthetic Genomics and Tryptamines. Its customers include Pharmaceutical Companies, Biotechnology Firms and Food and Beverage Industry.
CB Therapeutics has a B2B and White Label business model. Its revenue comes from Product Sales, Licensing and Project Based.
CB Therapeutics has approximately 15 employees.
CB Therapeutics has completed 7 funding rounds, raising a total of $7.62M. The latest funding stage is Series A.
CB Therapeutics offers: Development of rare compounds using synthetic biology, Production of cannabinoids, tryptamines, and peptides, AI-driven biosynthesis platform for enzyme and pathway design, Creation of animal-free food ingredients, Research and development for non-opioid pain management.
Top alternatives and competitors to CB Therapeutics include Berkeley Lights, CERo Therapeutics, Inc., Koniku, LifeMine Therapeutics, Hexagon Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CB Therapeutics and Berkeley Lights are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for CB Therapeutics, https://bouncewatch.com/company/cb-therapeutics, updated 19 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout